» Articles » PMID: 11734619

Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations

Overview
Journal Pharmacol Rev
Specialty Pharmacology
Date 2001 Dec 6
PMID 11734619
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Drug transport in the central nervous system is highly regulated not only by the blood-brain and the blood-cerebrospinal fluid barriers but also in brain parenchyma. The novel localization of drug transporters in brain parenchyma cells, such as microglia and astrocytes, suggest a reconsideration of the present conceptualization of brain barriers as it relates to drug transport. That is, the cellular membranes of parenchyma cells act as a second "barrier" to drug permeability and express transporters whose properties appear similar to those localized at the conventional brain barriers. This review will focus on the molecular characteristics, localization, and substrate specificities of several classes of well known membrane drug transporters (i.e., the organic cation, organic anion, nucleoside, P-glycoprotein, and multidrug resistance proteins) in the brain. Comparisons to similar transporters localized within the peripheral system and clinical implications of the functional expression of specific drug transport families will be discussed when appropriate. Nutrient and neurotransmitter transporters, whose characteristics have been reviewed extensively elsewhere, will not be considered in this review.

Citing Articles

Lipid-based nanoparticles for drug delivery in Parkinson's disease.

Cai H, Liu D, Xue W, Ma L, Xie H, Ning K Transl Neurosci. 2024; 15(1):20220359.

PMID: 39654878 PMC: 11627081. DOI: 10.1515/tnsci-2022-0359.


CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.

Sun M, Manson M, Guo T, de Lange E CNS Drugs. 2024; 38(5):349-373.

PMID: 38580795 PMC: 11026214. DOI: 10.1007/s40263-024-01082-3.


Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function.

Huang C, Hoque T, Bendayan R Front Pharmacol. 2023; 14:1118580.

PMID: 36969875 PMC: 10030948. DOI: 10.3389/fphar.2023.1118580.


Evidence for an alternative insulin transporter at the blood-brain barrier.

Banks W, Noonan C, Rhea E Aging Pathobiol Ther. 2023; 4(4):100-108.

PMID: 36644126 PMC: 9837797. DOI: 10.31491/apt.2022.12.100.


Engineering antibody and protein therapeutics to cross the blood-brain barrier.

Zhao P, Zhang N, An Z Antib Ther. 2022; 5(4):311-331.

PMID: 36540309 PMC: 9759110. DOI: 10.1093/abt/tbac028.